Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F13%3A33145239" target="_blank" >RIV/61989592:15110/13:33145239 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/S1470-2045(13)70464-9" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(13)70464-9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1470-2045(13)70464-9" target="_blank" >10.1016/S1470-2045(13)70464-9</a>
Alternative languages
Result language
angličtina
Original language name
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
Original language description
Background Population pharmacokinetic data suggest axitinib plasma exposure correlates with efficacy in metastatic renal-cell carcinoma. Axitinib dose titration might optimise exposure and improve outcomes. We prospectively assessed the efficacy and safety of axitinib dose titration in previously untreated patients with metastatic renal-cell carcinoma.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Lancet Oncology
ISSN
1470-2045
e-ISSN
—
Volume of the periodical
14
Issue of the periodical within the volume
12
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
1233-1242
UT code for WoS article
—
EID of the result in the Scopus database
—